FDA Clearance Tracker · K240902
Dexcom G7 Continuous Glucose Monitoring System
Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Apr 23, 2024
Substantially Equivalent
Time to decision
21 days
Received Apr 2, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K240902
- Device name
- Dexcom G7 Continuous Glucose Monitoring System
- Applicant
- Dexcom, Inc.
- Applicant location
- San Diego, CA
- Received
- Apr 2, 2024
- Decided
- Apr 23, 2024
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.1355
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QBJ. The earliest in FDA's data is DEN170088, decided Mar 27, 2018.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K240902
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Dexcom, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
K260935 · Decided Jun 12, 2026 · 84 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
- Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System510(k)
K261402 · Decided Jun 8, 2026 · 40 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.